HeraMED Limited (ASX: HMD), a digital health company transforming maternity care, announced it has secured AU$3.1 million through a two-tranche private placement at 1.7 cents per share—a 19% discount to the 15-day VWAP. The capital will support the commercial deployment and integration of its HeraCARE platform into health systems, clinics, and platforms across the US, Australia, and Europe.
Tranche 1 will raise approximately AU$2.623 million, with 154.3 million shares issued under ASX rules, while Tranche 2 will raise an additional AU$476,688 subject to shareholder approval in December 2024. Westar Capital managed the placement and will receive a 6% fee and 50 million options, subject to approval. CEO Anoushka Gungadin highlighted the importance of the funds in accelerating HeraMED’s strategic growth and tackling global maternity care challenges. The HeraCARE platform combines AI, cloud computing, and big data to enhance maternal healthcare, ensuring better outcomes at lower costs.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
